Scancell Holdings (SCLP) H1 2026 earnings summary

Executive summary

• Lead asset iSCIB1+ demonstrated 74% progression-free survival at 16 months in advanced melanoma, a 24% improvement over historical controls, with no increased toxicity, and best-in-class potential.

• FDA IND clearance received for iSCIB1+, with a Phase III registrational study planned for mid-2026 and potential commercialization in 2029.

• The ImmunoBody platform is validated, with patent protection to 2041 and scalable, off-the-shelf manufacturing.

• Additional pipeline assets include Modi-1 (Phase II for head and neck and renal cancer) and GlyMab antibody portfolio (preclinical), with ongoing partnering and financing discussions.

• GlyMab Therapeutics subsidiary established to advance antibody assets and strategic flexibility.

Financial highlights

• No revenues reported for the period; potential near-term milestones expected from partnered Genmab assets.

• Operating loss for six months ended 31 October 2025 was £8.9 million, improved from £10.5 million in the prior year period.

• Net loss after tax was £5.7 million, down from £12.5 million year-over-year.

• Cash and cash equivalents stood at £8.6 million as of 31 October 2025, with £3.0 million in R&D tax credits received post-period.

• Cash runway extends into H2 2026, with additional upside opportunities anticipated.

Outlook and guidance

• Phase III study for iSCIB1+ to begin in 2026, with commercialization possible in H2 2029, subject to financing or partnering.

• Pursuing U.S. fast-track status and regulatory clearances in the U.K. and Europe, with breakthrough designation in preparation.

• Data readout for Modi-1 expected in H1 2026, potentially enabling licensing opportunities.

• Ongoing evaluation of dual-track strategy: go-it-alone versus partnering for lead asset development.

• Additional Genmab milestones expected in 2026.